

Jonas Wetter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5705817/publications.pdf>

Version: 2024-02-01

68
papers

1,620
citations

279778

23
h-index

330122

37
g-index

70
all docs

70
docs citations

70
times ranked

2244
citing authors

#	ARTICLE	IF	CITATIONS
1	Complement C4 Copy Number Variation is Linked to SSA/Ro and SSB/La Autoantibodies in Systemic Inflammatory Autoimmune Diseases. <i>Arthritis and Rheumatology</i> , 2022, 74, 1440-1450.	5.6	17
2	Extramucosal Formation and Prognostic Value of Secretory Antibodies in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2022, 74, 801-809.	5.6	4
3	Variation of Complement Protein Levels in Maternal Plasma and Umbilical Cord Blood during Normal Pregnancy: An Observational Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 3611.	2.4	1
4	Associations of C-reactive protein isoforms with systemic lupus erythematosus phenotypes and disease activity. <i>Arthritis Research and Therapy</i> , 2022, 24, .	3.5	9
5	Circulating anti-citrullinated protein antibodies containing secretory component are prognostic for arthritis onset in at-risk patients. <i>Clinical and Experimental Immunology</i> , 2021, 204, 344-351.	2.6	4
6	Plasma osteopontin versus intima media thickness of the common carotid arteries in well-characterised patients with systemic lupus erythematosus. <i>Lupus</i> , 2021, 30, 096120332110138.	1.6	5
7	Pentraxin-3 detected in human saliva shows limited correlation with biomarkers associated with systemic inflammation. <i>Apmis</i> , 2021, 129, 304-313.	2.0	2
8	Comparison of Surrogate Markers of the Type I Interferon Response and Their Ability to Mirror Disease Activity in Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2021, 12, 688753.	4.8	12
9	Plasma C-Reactive Protein and Pentraxin-3 Reference Intervals During Normal Pregnancy. <i>Frontiers in Immunology</i> , 2021, 12, 722118.	4.8	12
10	The Complex Role of C-Reactive Protein in Systemic Lupus Erythematosus. <i>Journal of Clinical Medicine</i> , 2021, 10, 5837.	2.4	27
11	Elevated free secretory component in early rheumatoid arthritis and prior to arthritis development in patients at increased risk. <i>Rheumatology</i> , 2020, 59, 979-987.	1.9	4
12	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2020, 106, 102340.	6.5	27
13	Longitudinal anti-nuclear antibody (ANA) seroconversion in systemic lupus erythematosus: a prospective study of Swedish cases with recent-onset disease. <i>Clinical and Experimental Immunology</i> , 2020, 199, 245-254.	2.6	29
14	Presence of salivary IgA anti-citrullinated protein antibodies associate with higher disease activity in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2020, 22, 274.	3.5	15
15	P23...Longitudinal antinuclear antibody (ANA) seroconversion in systemic lupus erythematosus: a prospective study of swedish cases with recent-onset disease. , 2020, , .		0
16	P106...Pentameric, but not monomeric C-reactive protein, limits the snRNP-immune complex triggered type I interferon response: implications for lupus pathogenesis. , 2020, , .		0
17	C-Reactive Protein Levels in Systemic Lupus Erythematosus Are Modulated by the Interferon Gene Signature and CRP Gene Polymorphism rs1205. <i>Frontiers in Immunology</i> , 2020, 11, 622326.	4.8	26
18	Pronounced Diurnal Pattern of Salivary C-Reactive Protein (CRP) With Modest Associations to Circulating CRP Levels. <i>Frontiers in Immunology</i> , 2020, 11, 607166.	4.8	8

#	ARTICLE	IF	CITATIONS
19	The majority of Swedish systemic lupus erythematosus patients are still affected by irreversible organ impairment: factors related to damage accrual in two regional cohorts. <i>Lupus</i> , 2019, 28, 1261-1272.	1.6	22
20	Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. <i>Journal of Rheumatology</i> , 2019, 46, 492-500.	2.0	15
21	264...Damage accrual in swedish systemic lupus erythematosus: secondary sjögrens syndrome is among the factors associated with increased risk. , 2019, , .		0
22	Sex differences in clinical presentation of systemic lupus erythematosus. <i>Biology of Sex Differences</i> , 2019, 10, 60.	4.1	55
23	S2A:6...Soluble urokinase plasminogen activator receptor (supar) predicts the development of organ damage over 5 years in systemic lupus erythematosus: results from the slicc inception cohort. , 2018, , .		0
24	PS4:71...Iga anti-phospholipid antibodies in swedish cases with systemic lupus erythematosus: associations with disease phenotypes, vascular events and damage accrual. , 2018, , .		0
25	Active NET formation in Libman-“Sacks endocarditis without antiphospholipid antibodies: A dramatic onset of systemic lupus erythematosus. <i>Autoimmunity</i> , 2018, 51, 310-318.	2.6	11
26	Immunoglobulin A anti-phospholipid antibodies in Swedish cases of systemic lupus erythematosus: associations with disease phenotypes, vascular events and damage accrual. <i>Clinical and Experimental Immunology</i> , 2018, 194, 27-38.	2.6	16
27	Changes in anti-citrullinated protein antibody isotype levels in relation to disease activity and response to treatment in early rheumatoid arthritis. <i>Clinical and Experimental Immunology</i> , 2018, 194, 391-399.	2.6	17
28	Circulating cartilage oligomeric matrix protein in juvenile idiopathic arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2017, 46, 194-197.	1.1	6
29	Interferon-± coincides with suppressed levels of pentraxin-3 (PTX3) in systemic lupus erythematosus and regulates leucocyte PTX3 <i>in vitro</i>. <i>Clinical and Experimental Immunology</i> , 2017, 189, 83-91.	2.6	17
30	A single nucleotide polymorphism in the<i>NCF1</i> gene leading to reduced oxidative burst is associated with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1607-1613.	0.9	103
31	Osteopontin is associated with disease severity and antiphospholipid syndrome in well characterised Swedish cases of SLE. <i>Lupus Science and Medicine</i> , 2017, 4, e000225.	2.7	18
32	Long-term follow-up in primary Sjögren-™s syndrome reveals differences in clinical presentation between female and male patients. <i>Biology of Sex Differences</i> , 2017, 8, 25.	4.1	39
33	THU0345...Presence of Immunoglobulin (IG) A Antibodies against Cardiolipin and Î22-Glycoprotein-I in The Absence of IGG and IGM in Systemic Lupus Erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 312.1-312.	0.9	0
34	Antibodies against High Mobility Group Box protein-1 (HMGB1) versus other anti-nuclear antibody fine-specificities and disease activity in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2015, 17, 338.	3.5	27
35	Soluble urokinase plasminogen activator receptorâ€”A valuable biomarker in systemic lupus erythematosus?. <i>Clinica Chimica Acta</i> , 2015, 444, 234-241.	1.1	27
36	Four Anti-dsDNA Antibody Assays in Relation to Systemic Lupus Erythematosus Disease Specificity and Activity. <i>Journal of Rheumatology</i> , 2015, 42, 817-825.	2.0	57

#	ARTICLE	IF	CITATIONS
37	Quality of life and acquired organ damage are intimately related to activity limitations in patients with systemic lupus erythematosus. BMC Musculoskeletal Disorders, 2015, 16, 188.	1.9	43
38	Association of Serum C-reactive Protein Levels With Lupus Disease Activity in the Absence of Measurable Interferon- γ and a C-reactive Protein Gene Variant. Arthritis and Rheumatology, 2014, 66, 1568-1573.	5.6	30
39	THU0042...Autoantibodies against High Mobility Group Box Protein-1 in Systemic Lupus Erythematosus: Association with Disease Activity and Other Antinuclear Antibodies. Annals of the Rheumatic Diseases, 2014, 73, 191.1-191.	0.9	0
40	Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus. Translational Research, 2013, 162, 287-296.	5.0	43
41	C-reactive protein, immunoglobulin G and complement co-localize in renal immune deposits of proliferative lupus nephritis. Autoimmunity, 2013, 46, 205-214.	2.6	35
42	C1q regulates collagen-dependent production of reactive oxygen species, aggregation and levels of soluble P-selectin in whole blood. Immunology Letters, 2012, 142, 28-33.	2.5	10
43	IgG Rheumatoid Factors Against the Four Human Fc γ Subclasses in Early Rheumatoid Arthritis (The Swedish TIRA Project). Scandinavian Journal of Immunology, 2012, 75, 115-119.	2.7	3
44	Cell expansion of human articular chondrocytes on macroporous gelatine scaffolds—impact of microcarrier selection on cell proliferation. Biomedical Materials (Bristol), 2011, 6, 065001.	3.3	18
45	Beware of Antibodies to Dietary Proteins in “Antigen-specific” Immunoassays! Falsely Positive Anticytokine Antibody Tests Due to Reactivity with Bovine Serum Albumin in Rheumatoid Arthritis (The Tj ETQq1 12007843146gBT/O	1.2	1
46	Designed Surface with Tunable IgG Density as an in Vitro Model for Immune Complex Mediated Stimulation of Leukocytes. Langmuir, 2010, 26, 3493-3497.	3.5	2
47	C1q induces a rapid up-regulation of P-selectin and modulates collagen- and collagen-related peptide-triggered activation in human platelets. Immunobiology, 2010, 215, 987-995.	1.9	24
48	Interferon- γ mediates suppression of C-reactive protein: Explanation for muted C-reactive protein response in lupus flares?. Arthritis and Rheumatism, 2009, 60, 3755-3760.	6.7	78
49	Human articular chondrocytes on macroporous gelatin microcarriers form structurally stable constructs with blood-derived biological glues in vitro. Journal of Tissue Engineering and Regenerative Medicine, 2009, 3, 450-460.	2.7	35
50	Reduced serum levels of autoantibodies against monomeric C-reactive protein (CRP) in patients with acute coronary syndrome. Clinica Chimica Acta, 2009, 400, 128-131.	1.1	17
51	Serum levels of autoantibodies against C-reactive protein correlate with renal disease activity and response to therapy in lupus nephritis. Arthritis Research and Therapy, 2009, 11, R188.	3.5	39
52	Simultaneous use of electrochemistry and chemiluminescence to detect reactive oxygen species produced by human neutrophils. Cell Biology International, 2008, 32, 1486-1496.	3.0	15
53	C-reactive protein and C1q regulate platelet adhesion and activation on adsorbed immunoglobulin G and albumin. Immunology and Cell Biology, 2008, 86, 466-474.	2.3	20
54	Immobilized Chemoattractant Peptides Mediate Adhesion and Distinct Calcium-Dependent Cell Signaling in Human Neutrophils. Langmuir, 2008, 24, 6803-6811.	3.5	12

#	ARTICLE	IF	CITATIONS
55	Solid-phase classical complement activation by C-reactive protein (CRP) is inhibited by fluid-phase CRPâ€C1q interaction. Biochemical and Biophysical Research Communications, 2007, 352, 251-258.	2.1	35
56	Pathogenic implications for autoantibodies against C-reactive protein and other acute phase proteins. Clinica Chimica Acta, 2007, 378, 13-23.	1.1	48
57	Surface plasmon resonance detection of blood coagulation and platelet adhesion under venous and arterial shear conditions. Biosensors and Bioelectronics, 2007, 23, 261-268.	10.1	27
58	Tu-P10:452 C-reactive protein inhibit complement-mediated platelet activation suggesting a protective role in atherogenesis. Atherosclerosis Supplements, 2006, 7, 284.	1.2	0
59	Electrochemical characterization and application of azurin-modified gold electrodes for detection of superoxide. Biosensors and Bioelectronics, 2006, 22, 213-219.	10.1	22
60	Role of the actin cytoskeleton during respiratory burst in chemoattractant-stimulated neutrophils. Cell Biology International, 2006, 30, 154-163.	3.0	39
61	Whole blood coagulation on protein adsorption-resistant PEG and peptide functionalised PEG-coated titanium surfaces. Biomaterials, 2005, 26, 861-872.	11.4	140
62	Oxygen radical production in neutrophils interacting with platelets and surface-immobilized plasma proteins: Role of tyrosine phosphorylation. Journal of Biomedical Materials Research - Part A, 2003, 67A, 439-447.	4.0	22
63	Interactions between surface-bound actin and complement, platelets, and neutrophils. Journal of Biomedical Materials Research - Part A, 2003, 66A, 162-175.	4.0	19
64	Platelets stimulated by IgG-coated surfaces bind and activate neutrophils through a selectin-dependent pathway. Biomaterials, 2003, 24, 1559-1573.	11.4	28
65	On the binding of complement to solid artificial surfaces in vitro. Biomaterials, 2002, 23, 981-991.	11.4	53
66	The influence of plasma proteins and platelets on oxygen radical production and F-actin distribution in neutrophils adhering to polymer surfaces. Biomaterials, 2002, 23, 1785-1795.	11.4	56
67	C1q-independent activation of neutrophils by immunoglobulin M-coated surfaces. Journal of Biomedical Materials Research Part B, 2001, 57, 550-558.	3.1	23
68	Complement activation on immunoglobulin G-coated hydrophobic surfaces enhances the release of oxygen radicals from neutrophils through an actin-dependent mechanism. Journal of Biomedical Materials Research Part B, 2000, 51, 742-751.	3.1	36